Cite
Thompson JA, Shulman KL, Benyunes MC, et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol. 1992;10(6):960-8doi: 10.1200/JCO.1992.10.6.960.
Thompson, J. A., Shulman, K. L., Benyunes, M. C., Lindgren, C. G., Collins, C., Lange, P. H., Bush, W. H., Benz, L. A., & Fefer, A. (1992). Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10(6), 960-8. https://doi.org/10.1200/JCO.1992.10.6.960
Thompson, J A, et al. "Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 10,6 (1992): 960-8. doi: https://doi.org/10.1200/JCO.1992.10.6.960
Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH, Benz LA, Fefer A. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol. 1992 Jun;10(6):960-8. doi: 10.1200/JCO.1992.10.6.960. PMID: 1588376.
Copy
Download .nbib